[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vanda Pharmaceuticals\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":401},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,44,70,94,123,150,178,198,225,246,278,304,326,351,373],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100646670","phase-3-study-to-evaluate-the-efficacy-and-safety-of-ponesimod-vsp-128-in-patients-with-moderately-to-severely-active-ulcerative-colitis-100646670",false,"NCT07686081","Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ponesimod in Patients With Moderately to Severely Active Ulcerative Colitis","Inclusion Criteria:\n\n* Male and female subjects aged 18-75 years\n* Able to provide written informed consent\n* Diagnosis of ulcerative colitis for ≥90 days prior to screening\n* Three-component Mayo score of 5-9 with endoscopy subscore ≥2 and rectal bleeding subscore ≥1\n* History of inadequate response, loss of response, or intolerance to at least one approved UC therapy\n\nExclusion Criteria:\n\n* Severe or fulminant UC likely to require hospitalization or surgery\n* Diagnosis of Crohn's disease or other non-UC colitis\n* Prior exposure to S1P receptor modulators\n* Active or chronic infections\n* Clinically significant cardiovascular, hepatic, or other uncontrolled systemic disease\n* History of an allergic reaction or significant sensitivity to constituents of study drug","ALL","18 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis",[27],"Ulcerative Colitis (UC)",[29,30],"ulcerative colitis","moderately to severely active ulcerative colitis","RECRUITING","2026-08-14",{"date":34,"type":35},"2026-08-18","ACTUAL",{"date":37,"type":21},"2026-09",{"date":39,"type":21},"2029-08",{"name":41,"class":42},"Vanda Pharmaceuticals","INDUSTRY",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100620776","phase-3-open-label-study-to-investigate-the-safety-and-efficacy-of-ponesimod-in-moderate-to-severe-chronic-plaque-psoriasis-100620776","NCT07362017","Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis","A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis","Inclusion Criteria:\n\n* Male and female subjects aged 18-65 years, inclusive\n* BMI \\>18 and \\\u003C40\n* Minimum affected BSA of 10%\n* PASI score ≥ 12\n* PGA ≥ 3\n* Diagnosed with moderate-to-severe plaque psoriasis\n\nExclusion Criteria:\n\n* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis\n* History of an allergic reaction or known and\u002For significant sensitivity to study drug","65 Years",{"count":53,"type":21},300,[24],"An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis",[57],"Moderate-to-severe Chronic Plaque Psoriasis",[59,60],"psoriasis","Moderate-to-severe chronic plaque psoriasis","2026-06-10",{"date":63,"type":35},"2026-06-11",{"date":65,"type":35},"2026-02-17",{"date":67,"type":21},"2028-12",{"name":41,"class":42},4,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100589396","phase-3-evaluating-the-effects-of-tasimelteon-vs-placebo-in-treating-pediatric-insomnia-100589396","NCT06953869","Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia","A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent of the participant or legal guardian (and assent as required).\n* Confirmed clinical diagnosis of insomnia disorder\n* Males and Females between 2 and 17 years, inclusive.\n* The sleep disturbance must not be a result of another medication.\n\nExclusion Criteria:\n\n* Inability to dose daily with tasimelteon or previous intolerance to tasimelteon.\n* Indication of impaired liver function.\n* Pregnant or lactating females.\n* A positive test for drugs of abuse.","2 Years","17 Years",{"count":80,"type":21},420,[24],"This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.",[84],"Insomnia Disorder","2026-06-03",{"date":87,"type":35},"2026-06-05",{"date":89,"type":35},"2025-04-21",{"date":91,"type":21},"2028-01",{"name":41,"class":42},35,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100627269","phase-3-a-study-to-evaluate-tradipitant-on-treating-nausea-and-vomiting-induced-by-glp-1r-agonist-use-100627269","NCT07446439","A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers","Inclusion Criteria:\n\n* Body Mass Index ≥ 25 and \\\u003C 40 kg\u002Fm\\^2\n* No serious medical problems or chronic diseases, specifically no type I or type II diabetes\n\nExclusion Criteria:\n\n* Another disorder that contributes to gastrointestinal symptoms\n* History of intolerance and\u002For hypersensitivity to NK-1 receptor antagonists\n* History of intolerance and\u002For hypersensitivity to GLP-1 receptor agonists\n* Exposure to any investigational medication within the past 60 days",true,{"count":103,"type":21},280,[24],"The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.",[107,108],"Nausea and Vomiting","Obesity",[110,111,112,113],"GLP-1R agonist","Semaglutide","Nausea","Vomiting","2026-04-14",{"date":116,"type":35},"2026-04-20",{"date":118,"type":35},"2026-03-27",{"date":120,"type":21},"2026-12-01",{"name":41,"class":42},10,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100350139","phase-1-tolerability-study-of-trichostatin-a-in-subjects-with-relapsed-or-refractory-hematologic-malignancies-100350139","NCT03838926","Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n* Subject is ≥ 18 years at the time of signing informed consent;\n* Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;\n* Presence of measurable or evaluable disease;\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;\n* Contraceptives or other approved avoidance of pregnancy measures\n\nExclusion Criteria:\n\n* Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;\n* Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);\n* Undergone major surgery ≤ 2 weeks prior to starting study drug;\n* Evidence of mucosal or internal bleeding;\n* Impaired cardiac function or conduction defect;\n* Concurrent severe and\u002For uncontrolled medical conditions",{"count":130,"type":21},42,[132],"PHASE1","The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.",[135],"Relapsed or Refractory Hematologic Malignancies",[137,138,139,140],"Hematologic","Malignancies","Cancer","Blood","2026-03-12",{"date":143,"type":35},"2026-03-16",{"date":145,"type":35},"2018-09-27",{"date":147,"type":21},"2027-12",{"name":41,"class":42},11,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100599874","phase-2-evaluation-of-efficacy-and-safety-of-iloperidone-for-the-treatment-of-participants-with-uncontrolled-hypertension-100599874","NCT07090161","Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension","Inclusion Criteria:\n\n* SiSBP \\>\u002F= 130 mmHg despite \\>8 weeks treatment w\u002F 1 or more antihypertensive therapies\n\nExclusion Criteria:\n\n* Confirmed Grade 3\u002Fsevere hypertension (SiSBP \\>\u002F= 180 mmHg, SiDBP \\>\u002F= 120 mmHg), unstable cardiac disease, renal insufficiency",{"count":158,"type":21},240,[160],"PHASE2","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension",[163,164],"Hypertension","Uncontrolled Hypertension",[166,167,168],"iloperidone","hypertension","uncontrolled hypertension","2026-02-25",{"date":171,"type":35},"2026-02-27",{"date":173,"type":35},"2025-09-15",{"date":175,"type":21},"2026-11",{"name":41,"class":42},28,{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100579880","phase-3-evaluation-of-efficacy-and-safety-of-milsaperidone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-100579880","NCT06830044","Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder","A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","Inclusion Criteria:\n\n* Male or female patient 18 to 65 years of age, inclusive;\n* Meets DSM-5-TR criteria for MDD\n* Currently having an inadequate response to antidepressant therapy as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ)\n\nExclusion Criteria:\n\n* Within the patients lifetime, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD\n* Within 6 months of Screening, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD\n* Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment",{"count":186,"type":21},500,[24],"The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder",[190],"Major Depressive Disorder (MDD)",{"date":171,"type":35},{"date":193,"type":35},"2025-03-03",{"date":195,"type":21},"2028-03",{"name":41,"class":42},38,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100590019","phase-3-randomized-withdrawal-study-in-patients-with-schizophrenia-100590019","NCT06961968","Randomized Withdrawal Study in Patients With Schizophrenia","A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection","Inclusion Criteria:\n\n* Males or females 18 to 65 years of age (inclusive)\n* Diagnosed with schizophrenia per DSM-5 criteria\n* In need of ongoing psychiatric treatment\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months",{"count":206,"type":21},400,[24],"The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.",[210],"Schizophrenia",[210,212,213,214,215],"Antipsychotic Agents","Iloperidone","Long-Acting Injection","Randomized Withdrawal","2026-01-09",{"date":218,"type":35},"2026-01-12",{"date":220,"type":35},"2025-05-14",{"date":222,"type":21},"2027-11",{"name":41,"class":42},22,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":244,"locationsCount":245},"100606707","phase-2-an-eight-week-study-to-evaluate-the-safety-and-efficacy-of-vsj-110-compared-to-placebo-in-the-treatment-of-dry-eye-100606707","NCT07179055","An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye","An Eight-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye","Inclusion Criteria:\n\n* Be at least 18 years of age of either gender and any race.\n* Provide written informed consent and sign the HIPAA form.\n* Be willing and able to follow all instructions and attend all study visits.\n\nExclusion Criteria:\n\n* Use of any of the disallowed medications during the washout and study period.",{"count":233,"type":21},160,[160],"The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.",[237],"Dry Eye","2025-09-10",{"date":240,"type":35},"2025-09-17",{"date":242,"type":21},"2025-10",{"date":37,"type":21},{"name":41,"class":42},5,{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":253,"enrollmentInfo":4,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":273,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":277,"locationsCount":5},"100398963","single-patient-expanded-access-protocol-for-tradipitant-in-a-single-patient-with-gastroparesis-100398963","NCT04474990","Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","VP-VLY-686-3303: Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","Inclusion Criteria:\n\n* Identified subject who requested expanded access\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Patient does not qualify for or does not have access to other clinical trials with tradipitant;\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits;\n* Exposure to any investigational medication in the past 60 days other than tradipitant\n* Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year\n* Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit ratio to treatment;","70 Years","EXPANDED_ACCESS","Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant",[257,258],"Gastroparesis","Diabetic Gastroparesis",[260,261,262,263,264,265,266,267,268,269,270,271,272],"gastroparesis","idiopathic","diabetic","tradipitant","nausea","vomiting","stomach","motility","functional","NK-1 antagonist","neurokinin 1 receptor","substance p","expanded access","AVAILABLE","2025-08-18",{"date":276,"type":35},"2025-08-24",{"name":41,"class":42},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":285,"maxAge":78,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":303},"100489090","phase-4-safety-and-tolerability-of-open-labeled-iloperidone-in-adolescents-100489090","NCT05648591","Safety and Tolerability of Open-Labeled Iloperidone in Adolescents","Open-label Safety Study of a 1-year 8 to 24 mg\u002FDay Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder","Inclusion Criteria:\n\n* Patient is willing and able to provide assent and willing to complete all aspects of the study\n* Patient's parent or legal guardian willing and able to provide consent\n* Male or female patients 12 through 17 years of age (inclusive)\n* Clinical diagnosis of either schizophrenia or bipolar I disorder\n\nExclusion Criteria:\n\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer\n* A positive test for drugs of abuse","12 Years",{"count":287,"type":21},100,[289],"PHASE4","To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.",[210,292],"Bipolar I Disorder",[294],"fanapt","2025-02-27",{"date":297,"type":35},"2025-03-04",{"date":299,"type":35},"2023-05-24",{"date":301,"type":21},"2026-11-30",{"name":41,"class":42},9,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":253,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":325},"100580381","phase-3-open-label-safety-study-of-tradipitant-in-idiopathic-and-diabetic-gastroparesis-100580381","NCT06836557","Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis","A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis","Inclusion Criteria:\n\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Body Mass Index (BMI) of ≥18 and ≤40 kg\u002Fm2\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits\n* Pregnancy or nursing\n* Evidence of uncontrolled blood glucose (including HbA1C \\>11% at screening or metabolic crisis in past 60 days)",{"count":287,"type":21},[24],"This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.",[315,258,257],"Idiopathic Gastroparesis",[260,261,262,263,264,265,266,267,268,269,270,271],"2025-02-14",{"date":319,"type":35},"2025-02-20",{"date":321,"type":35},"2024-01-09",{"date":323,"type":21},"2025-12",{"name":41,"class":42},3,{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":350},"100569988","phase-3-evaluating-the-effects-of-tasimelteon-vs-placebo-in-delayed-sleep-wake-phase-disorder-dswpd-and-the-cry111-variant-100569988","NCT06701396","Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","A Double-Blind, Randomized, Two-Period Crossover Study to Evaluate the Effects of Tasimelteon Vs. Placebo in Subjects with Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","Inclusion Criteria:\n\n* Ability and acceptance to provide written informed consent.\n* A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).\n* Carrier of CRY1Δ11 variant.\n* Men or women between 18 - 75 years, inclusive.\n* Body Mass Index (BMI) of ≥ 18 and ≤ 40 kg\u002Fm\\^2.\n\nExclusion Criteria:\n\n* Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.\n* Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.\n* A positive test for substances of abuse.\n* Current tobacco user.",{"count":334,"type":21},60,[24],"This is a double-blind, randomized, two-period crossover study to evaluate the efficacy and safety of a single oral dose of tasimelteon and matching placebo in male and female subjects with DSWPD and the CRY1Δ11 variant.",[338,339,340,341],"Sleep Wake Disorders","Sleep Disorders, Circadian Rhythm","Chronobiology Disorders","Gene Mutations and Other Alterations Nec","2024-11-19",{"date":344,"type":35},"2024-11-22",{"date":346,"type":35},"2024-10-08",{"date":348,"type":21},"2025-06-30",{"name":41,"class":42},1,{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":358,"maxAge":51,"enrollmentInfo":359,"targetDuration":4,"studyType":361,"phases":4,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":350},"100297645","development-of-clinical-database-of-individuals-with-smith-magenis-syndrome-and-sleep-disturbances-100297645","NCT03154697","Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances","Development of Clinical Database of Individuals With Smith-Magenis Syndrome","Inclusion Criteria:\n\n* Parent or legal guardian of individual with Smith-Magenis Syndrome\n\nExclusion Criteria:\n\n* Not legal guardian of individual with SMS","3 Years",{"count":360,"type":21},1000,"OBSERVATIONAL","This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.",[364],"Sleep Disturbances in Smith-Magenis Syndrome","2024-03-19",{"date":367,"type":35},"2024-03-20",{"date":369,"type":35},"2016-01",{"date":371,"type":21},"2030-12",{"name":41,"class":42},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":361,"phases":4,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":350},"100147817","patient-registry-of-blind-subjects-with-sleep-related-problems-100147817","NCT01195558","Patient Registry of Blind Subjects With Sleep-related Problems","Development of a Patient Registry of Blind Subjects With Sleep-related Problems","Inclusion Criteria:\n\n1. Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria.\n2. Subjects must be blind.\n3. Subjects must have some self-described problem with sleep or daytime sleepiness.",{"count":381,"type":21},10000,"Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.",[384],"Sleep-wake Disorder in Blind Individuals",[386,387,388,389,390,391,392],"Non-24","N24HSWD","Blindness","Sleep","Wake","Circadian Rhythm","Nap","2020-06-22",{"date":395,"type":35},"2020-06-24",{"date":397,"type":4},"2010-04",{"date":399,"type":21},"2030-04",{"name":41,"class":42},""]